SDGRSchrödinger, Inc.

$20.03

The financials

Schrödinger, Inc. by the numbers

Schrödinger, Inc. (SDGR) reported revenue of $59M in Q1 2026 (quarter ended Mar 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $60M. For the full year FY2025, revenue was $256M (+23% year on year) and net income −$103M. Its largest product in Jun 2026 was Drug Discovery at $23M, 40% of the disclosed total, ahead of Hosted Software at 26%.

Schrödinger, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$59M$60M−1.6%
Gross profit$30M$31M−5.1%
Operating income−$49M−$51Mn/a
Net income−$60M−$60Mn/a
Diluted EPS−$0.81−$0.82n/a
Revenue by product, Jun 2026, as reported to the SEC
ProductRevenueShare
Drug Discovery$23M40%
Hosted Software$15M26%
Drug Discovery Services$8.8M15%
Contribution$3.4M5.9%
Professional Services$3.2M5.6%
Software Contribution$2.9M5.1%
Oncology Neurology And Immunology Product$500K0.9%
Drug Discovery Contribution$438K0.8%
Software Products And Services$3K0.0%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Jun 2026Total $57.4M (+14%)
Drug Discovery grew +65% year on yearSoftware Products And Services -73% year on year
  • Drug Discovery$23.0MQoQ +0.47%year on year +65%
  • Hosted Software$15.2MQoQ +25%year on year +36%
  • Drug Discovery Services$8.8MQoQ -25%year on year +16%
  • Contribution$3.4MQoQ +4565%year on year -29%
  • Professional Services$3.2MQoQ +22%year on year +35%
  • Software Contribution$2.9MQoQ -year on year -35%
  • Oncology Neurology And Immunology Product$500.0KQoQ -29%year on year -29%
  • Drug Discovery Contribution$438.0KQoQ +196%year on year +59%
  • Software Products And Services$3.0KQoQ 0.00%year on year -73%
Segment sum = 97% of reported consolidated revenue · Latest source: 10-Q filed 2026-08-05, SEC EDGAR